ReviewPLOS digital health2026
Clinical artificial intelligence applications of vision-language foundation models.
Review in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vision-language models (VLMs) represent a transformative advance in generative artificial intelligence (AI), using multimodal data processing to enhance clinical decision-making and workflow efficiency. Built on transformer architectures, VLMs excel in tasks like image interpretation, report generation, and visual question-answering, with emerging applications in radiology, pathology, and broader clinical practice. Their potential extends to automating documentation, improving medical education, and assisting with clinical decision-making in real-time. However, successful integration requires rigorous validation to address challenges such as bias, interpretability, and safety concerns. Prospective clinical trials, health economic evaluations, and stakeholder engagement are essential to ensure equitable and effective deployment. Regulatory frameworks must evolve to accommodate VLM functionality while maintaining accountability and protecting patient safety. By balancing innovation with robust oversight, VLMs hold promise in reducing clinician workload, expanding access to expert care, and advancing precision medicine-ushering in a new era of AI-augmented healthcare.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.